---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-005471"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:20:50.961626+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# DiaMedica appoints Tanya Lewis to board; Burroughs resigns

## Summary
- Amy L. Burroughs resigned as director effective March 1, 2023; no disagreement with company.
- Tanya N. Lewis appointed to fill vacancy, effective March 1, 2023.
- Lewis is Chief Development Operations Officer at Replimune (Nasdaq:REPL) with 25+ years drug development experience.
- Lewis received option to purchase 26,443 shares at $1.77/share, vesting quarterly over 3 years.
- Company working to resolve clinical hold on ReMEDy2 AIS trial.

## SEC filing metadata
- accession: 0001437749-23-005471
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774923005471/0001437749-23-005471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774923005471/dmtp20230303_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-005471
- JSON: https://secwatch.observer/filing/0001437749-23-005471.json
- Plain text: https://secwatch.observer/filing/0001437749-23-005471.txt

## Key facts
- Executive change
  Tanya N. Lewis was appointed as director at DiaMedica Therapeutics Inc..
  - Action: appointed
  - Role: director
  source text: To fill the vacancy created by Ms. Burroughs’s resignation, on March 1, 2023, the Company’s Board of Directors (the “Board”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tanya N. Lewis to the Board, effective immediately, to fill the vacancy created by Ms. Burroughs’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774923005471/0001437749-23-005471-index.htm
- Executive change
  Amy L. Burroughs resigned as director at DiaMedica Therapeutics Inc..
  - Action: resigned
  - Role: director
  source text: On March 1, 2023, Amy L. Burroughs resigned as a director of DiaMedica Therapeutics Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774923005471/0001437749-23-005471-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.